Skip to main content
SpringerLink
Log in
Book cover

Tumors of the Central Nervous System, Volume 1 pp 291–298Cite as

Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma

  • Chapter
  • First Online:

  • 1833 Accesses

Part of the book series: Tumors of the Central Nervous System ((TCNS,volume 1))

Abstract

The endoplasmic reticulum (ER) stress response constitutes an adaptive mechanism that sustains cellular survival under adverse microenvironmental and other stress conditions, and thereby also supports chemoresistance of tumor cells. Due to their enhanced proliferation rate in combination with oftentimes limited blood supply, tumor cells frequently experience long-lasting, chronic ER stress conditions that set them apart from normal cells, and this differential may provide opportunities for pharmacologic intervention. The proteasome inhibitor bortezomib and the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib have been shown to aggravate pre-existing ER stress in glioblastoma cells, and when combined exert synergistic tumoricidal effects in vivo. Thus, this particular drug combination may hold promise as a novel therapeutic strategy for glioblastoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Adams J, Kauffman M (2004) Development of the proteasome inhibitor velcade (bortezomib). Cancer Invest 22:304–311

    Article  PubMed  CAS  Google Scholar 

  • Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB (2007) Autophagy inhibition enhances therapy-induced apoptosis in a myc-induced model of lymphoma. J Clin Invest 117:326–336

    Article  PubMed  CAS  Google Scholar 

  • Bittner B, Thelly T, Isel H, Mountfield RJ (2000) The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. Int J Pharm 205:195–198

    Article  PubMed  CAS  Google Scholar 

  • Boyce M, Yuan J (2006) Cellular response to endoplasmic reticulum stress: a matter of life or death. Cell Death Differ 13:363–373

    Article  PubMed  CAS  Google Scholar 

  • Briceno E, Calderon A, Sotelo J (2007.) Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 67:388–391

    Article  PubMed  Google Scholar 

  • Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome bcr-abl-mediated drug resistance. Blood 110:313–322

    Article  PubMed  CAS  Google Scholar 

  • Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 39:267–274

    Article  PubMed  CAS  Google Scholar 

  • Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230–233

    Article  PubMed  CAS  Google Scholar 

  • Chuang H-C, Kardosh A, Gaffney KJ, Petasis NA, Schönthal AH (2008) COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol Cancer 38

    Google Scholar 

  • Denmeade SR, Isaacs JT (2005) The SERCA pump as a therapeutic target: making a “smart bomb” for prostate cancer. Cancer Biol Ther 4:14–22

    Article  PubMed  CAS  Google Scholar 

  • Dogne JM, Hanson J, Supuran C, Pratico D (2006) Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 12:971–975

    Article  PubMed  CAS  Google Scholar 

  • Fribley A, Zeng Q, Wang CY (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:9695–9704

    Article  PubMed  CAS  Google Scholar 

  • Grösch S, Maier TJ, Schiffmann S, Geisslinger G (2006.) Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 98:736–747

    Article  PubMed  Google Scholar 

  • Hemeryck A, Geerts R, Monbaliu J, Hassler S, Verhaeghe T, Diels L, Verluyten W, van Beijsterveldt L, Mamidi RN, Janssen C, De Coster R (2007) Tissue distribution and depletion kinetics of bortezomib and bortezomib-related radioactivity in male rats after single and repeated intravenous injection of 14 C-bortezomib. Cancer Chemother Pharmacol 60:777–787

    Article  PubMed  CAS  Google Scholar 

  • Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC (2005) Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 102:8567–8572

    Article  PubMed  CAS  Google Scholar 

  • Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR (2006) Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 66:358–368

    Article  PubMed  CAS  Google Scholar 

  • Kang KB, Wang TT, Woon CT, Cheah ES, Moore XL, Zhu C, Wong MC (2007) Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 67:888–896

    Article  PubMed  CAS  Google Scholar 

  • Kardosh A, Blumenthal M, Wang WJ, Chen TC, Schönthal AH (2004) Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther 3:9–16

    Google Scholar 

  • Kardosh A, Golden EB, Pyrko P, Uddin J, Hofman FM, Chen CT, Louie SG, Petasis NA, Schönthal AH (2008) Aggravated endoplasmic reticulum (ER) stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analog, 2,5-dimethyl-celecoxib. Cancer Res 68:843–851

    Article  PubMed  CAS  Google Scholar 

  • Kardosh A, Soriano N, Pyrko P, Liu YT, Jabbour M, Hofman FM, Schonthal AH (2007) Reduced survivin expression and tumor cell survival during chronic hypoxia and further cytotoxic enhancement by the cyclooxygenase-2 inhibitor celecoxib. J Biomed Sci 14:647–662

    Article  PubMed  CAS  Google Scholar 

  • Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003.) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738

    Article  PubMed  CAS  Google Scholar 

  • Koki AT, Masferrer JL (2002) Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control 9:28–35

    PubMed  Google Scholar 

  • Lee AS (2007) GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Res 67:3496–3499

    Article  PubMed  CAS  Google Scholar 

  • Li J, Lee AS (2006) Stress induction of GRP78/BiP and its role in cancer. Curr Mol Med 6:45–54

    Article  PubMed  CAS  Google Scholar 

  • Marciniak SJ, Ron D (2006) Endoplasmic reticulum stress signaling in disease. Physiol Rev 86:1133–1149

    Article  PubMed  CAS  Google Scholar 

  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC (2002) Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 99:14374–14379

    Article  PubMed  CAS  Google Scholar 

  • Nawrocki ST, Carew JS, Pino MS, Highshaw RA, Andtbacka RH, Dunner K Jr., Pal A, Bornmann WG, Chiao PJ, Huang P, Xiong H, Abbruzzese JL, McConkey DJ (2006) Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 66:3773–3781

    Article  PubMed  CAS  Google Scholar 

  • Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11:381–389

    Article  PubMed  CAS  Google Scholar 

  • Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson Gd, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isakson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 h-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347–1365

    Article  PubMed  CAS  Google Scholar 

  • Pyrko P, Kardosh A, Schönthal AH (2008) Celecoxib transiently inhibits protein synthesis. Biochem Pharmacol 75:395–404

    Article  PubMed  CAS  Google Scholar 

  • Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS (2007) The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67:9809–9816

    Article  PubMed  CAS  Google Scholar 

  • Pyrko P, Soriano N, Kardosh A, Liu YT, Uddin J, Petasis NA, Hofman FM, Chen CS, Chen TC, Schönthal AH (2006) Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5(19)

    Google Scholar 

  • Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM, Mori K, Sadighi Akha AA, Raden D, Kaufman RJ (2006) Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 4:e374

    Article  PubMed  Google Scholar 

  • Schönthal AH (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioblastoma therapy. Neurosurg Focus 20(E21):1–10

    Google Scholar 

  • Schönthal AH (2007) Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy. Br J Cancer 97:1465–1468

    Article  PubMed  Google Scholar 

  • Schönthal AH (2009) Endoplasmic reticulum stress and autophagy as targets for cancer therapy. Cancer Lett 275:163–169

    Article  PubMed  Google Scholar 

  • Schönthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA (2008) Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 17:197–208

    Article  PubMed  Google Scholar 

  • Suzuki T, Lu J, Zahed M, Kita K, Suzuki N (2007) Reduction of GRP78 expression with siRNA activates unfolded protein response leading to apoptosis in HeLA cells. Arch Biochem Biophys 468:1–14

    Article  PubMed  CAS  Google Scholar 

  • Treiman M, Caspersen C, Christensen SB (1998) A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum ca(2+)-ATPases. Trends Pharmacol Sci 19:131–135

    Article  PubMed  CAS  Google Scholar 

  • Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS (2002) Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J Natl Cancer Inst 94:1745–1757

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

I am a grateful recipient of a grant from the National Brain Tumor Society (NBTS), and my research efforts are generously supported by NBTS’s Mickey McDonald Welker Chair of Research.

Author information

Authors and Affiliations

  1. Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA

    Axel H. Schönthal

Authors
  1. Axel H. Schönthal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel H. Schönthal .

Editor information

Editors and Affiliations

  1. Dept. Biological Sciences, Kean University, 1000 Moris Avenue, Union, 07083, New Jersey, USA

    M. A. Hayat

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Schönthal, A.H. (2011). Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 1. Tumors of the Central Nervous System, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0344-5_30

Download citation

  • DOI: https://doi.org/10.1007/978-94-007-0344-5_30

  • Published:

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-007-0343-8

  • Online ISBN: 978-94-007-0344-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation